ChemBriefFrench Biotech Company Ipsen to Buy Kartos Therapeutics for $450 Million
French biotech firm Ipsen agreed to acquire U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with late-stage blood cancer treatment navtemadlin. The transaction includes
reuters · 2026-06-29 01:14